JAMA Cardiology—The Year in Review, 2022

In our annual review of JAMA Cardiology, I am pleased to report that 2022 marked another year of steady growth in publishing original science, reviews, and opinion articles covering the areas of cardiology of interest to our readers.We received 2279 manuscripts (Table ), including 1832 original science submissions, which is comparable to prepandemic submissions in 2019.Submissions related to the pandemic and its cardiovascular ramifications totaled 118 (7.9% of total submissions), compared with 12.3% in 2021 and 24.7% in 2020.JAMA Cardiology continues to be a global journal with more than 60% of submissions arriving from outside the US.The journal's acceptance rate of 6% for original science manuscripts is on par with that of the other major journals in our field.The continuous flow of manuscripts adds to the workload of our very busy editors, but we relish the new knowledge and opinions that we see, evaluate, and discuss each week in our manuscript review meeting.We continue to learn from each other and our authors, peer reviewers, 7 and colleagues around the world.JAMA Cardiology's impact factor was 30.2 in 2022 (which is reported for 2021).The journal's weekly online content is now delivered to more than 97 000 readers, with 3.3 million annual article views and downloads.We maintain an active presence on social media, with an increase during the past year to more than 114 000 Twitter and Facebook followers.The JAMA Cardiology monthly podcast 8 discussions with authors remain highly popular.The close linkage of this journal to JAMA and the other JAMA Network journals connects us to the dedicated editorial and publication staff who facilitate the dissemination of the journal's content each week and amplify the reach of published content through multimedia, social media, and news media channels.Articles published in JAMA Cardiology in 2022 received mention in more than 7000 news reports.It is difficult this early in the new year to recognize which manuscripts published in 2022 will ultimately have the greatest impact, but we can identify those that received the most views and downloads, the highest Altmetric scores (measures of news and social media coverage), and the greatest number of citations in 2022 (Table ).The most notable of these was the study by Karlstad et al 1 examining the incidence of myocarditis diagnoses associated with vaccination for COVID-19 among 23.1 million individuals in the 4 Nordic countries.This report indicated that the incidence of myocarditis following administration of a messenger RNA (mRNA) vaccine was highest in male individuals aged 16 to 24 years, particularly after the second dose.But even in this highest-risk group, the incidence of myocarditis was low, estimated to be 5.5 events per 100 000 persons after the second dose of BNT162b2 and 18.4 events per 100 000 persons after the second dose of mRNA-1273.These findings confirmed the ongoing surveillance data from the US Centers for Disease Control and Prevention.